Role of saroglitazar in potential live liver donors with mild to moderate hepatic steatosis on initial non-enhanced computed tomography of liver

Abstract

Background and Aim: Live donor liver transplantations account for more than 95% of liver transplantations in our institute. A population-based study in Kerala showed the prevalence of NAFLD in the general population to be 49.8%. Its reflected in our transplant program, with > 10% hepatic steatosis being the most common reason for rejection as liver donors. We aimed to assess the efficacy and safety of Saroglitazar (PPAR agonist) in potential live liver donors with >10% hepatic steatosis as evidenced by a non-enhanced CT liver.